Trial Profile
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro) and Calcium Acetate (Phoslyra) in Paediatric and Adolescent CKD Patients With Hyperphosphataemia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2022
Price :
$35
*
At a glance
- Drugs Sucroferric oxyhydroxide (Primary) ; Calcium acetate
- Indications Hyperphosphataemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Vifor Fresenius Medical Care Renal Pharma
- 17 Apr 2019 Status changed from recruiting to discontinued.
- 05 Apr 2019 This trial has been discontinued in Germany, according to European Clinical Trials Database.
- 28 Mar 2019 This trial has been discontinued in Lithuania